^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PSMA-targeted antibody-drug conjugate

    Related drugs:
    2d
    A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, T.O.A.D. Oncology SA
    New P1/2 trial
    8d
    GenSci143 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P1 trial • First-in-human
    1m
    An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients with Advanced Solid Tumors. (ChiCTR2500110610)
    P1, N=150, Not yet recruiting, Zhejiang Cancer Hospital; Hangzhou DAC Biotechnology Co.,Ltd.
    New P1 trial • First-in-human
    2ms
    A Study of MHB048C in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P1/2 trial
    3ms
    A Study of DXC014 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Hangzhou DAC Biotechnology Co., Ltd.
    New P1 trial • First-in-human
    3ms
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors (clinicaltrials.gov)
    P1, N=110, Recruiting, Hangzhou DAC Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=110, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    JNJ-8177 • pasritamig (JNJ-8343)
    4ms
    A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=110, Not yet recruiting, Janssen Research & Development, LLC
    New P1 trial
    |
    JNJ-8177 • pasritamig (JNJ-8343)
    5ms
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=253, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: May 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    6ms
    A Phase I, Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of DXC008 in Patients with Prostate Cancer and Other Solid Tumors (such as Ewing Sarcoma) (ChiCTR2500100610)
    P2, N=110, Not yet recruiting, Peking University First Hospital; Hunan Cancer Hospital; Hangzhou DAC Biotechnology Co.,Ltd.
    New P2 trial
    8ms
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=253, Recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2028 --> Sep 2026
    Trial completion date
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    12ms
    Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review). (PubMed, Oncol Rep)
    In the present review, the developmental course, composition and mechanism of action of ADCs are explored, with a specific focus on recently published studies and ongoing trials aimed at investigating the efficacy and safety of ADCs in treating PCa. Lastly, ongoing challenges in ADC development and corresponding strategies to combat them are discussed.
    Review • Journal
    |
    CD276 (CD276 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • STEAP1 (STEAP Family Member 1) • CD46 (CD46 Molecule)